HAEMONETICS ($HAE) posted quarterly earnings results for Q3 2026 on Thursday, February 5th. The company reported earnings of $1.31 per share, beating estimates of $1.26 by $0.05. The company also reported revenue of $338,970,000, beating estimates of $334,931,756 by $4,038,244.
You can see Quiver Quantitative's $HAE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HAEMONETICS Insider Trading Activity
HAEMONETICS insiders have traded $HAE stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HAE stock by insiders over the last 6 months:
- MARK W KROLL purchased 1,400 shares for an estimated $98,784
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HAEMONETICS Hedge Fund Activity
We have seen 156 institutional investors add shares of HAEMONETICS stock to their portfolio, and 175 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 1,829,150 shares (-85.2%) from their portfolio in Q3 2025, for an estimated $89,152,771
- AQR CAPITAL MANAGEMENT LLC added 1,678,630 shares (+372.8%) to their portfolio in Q3 2025, for an estimated $81,816,426
- CAPITAL RESEARCH GLOBAL INVESTORS removed 1,139,043 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $55,516,955
- UBS GROUP AG removed 912,894 shares (-62.8%) from their portfolio in Q4 2025, for an estimated $73,168,454
- SG CAPITAL MANAGEMENT LLC removed 906,892 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $44,201,916
- MILLENNIUM MANAGEMENT LLC added 735,592 shares (+1957.0%) to their portfolio in Q3 2025, for an estimated $35,852,754
- VICTORY CAPITAL MANAGEMENT INC removed 707,833 shares (-90.9%) from their portfolio in Q3 2025, for an estimated $34,499,780
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HAEMONETICS Government Contracts
We have seen $82,487 of award payments to $HAE over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- BLOOD ADDITIVE SOLUTION FOR NAVAL HOSPITAL GUAM: $23,519
- EXPRESS REPORT: EXPRESS REPORT: NX ORDERS PLACED DURING THE MONTHS OF JAN-MAY 2025.: $22,660
- (R) HAEMONETICS CORPORATION:1177264 [25-002935] AUTOMATED CELL PROCESSORS ACP 215 SERIAL NUMBER 19C027SPG ...: $12,166
- TEG ANALYZERS: $8,148
- HAEMONETICS CORPORATION:1177264 [24-006940]: $8,148
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
HAEMONETICS Analyst Ratings
Wall Street analysts have issued reports on $HAE in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 12/17/2025
- BTIG issued a "Buy" rating on 11/21/2025
- Barrington Research issued a "Outperform" rating on 11/07/2025
- Raymond James issued a "Outperform" rating on 08/11/2025
To track analyst ratings and price targets for HAEMONETICS, check out Quiver Quantitative's $HAE forecast page.
HAEMONETICS Price Targets
Multiple analysts have issued price targets for $HAE recently. We have seen 8 analysts offer price targets for $HAE in the last 6 months, with a median target of $88.0.
Here are some recent targets:
- Michael Petusky from Barrington Research set a target price of $93.0 on 02/02/2026
- Marie Thibault from BTIG set a target price of $88.0 on 01/09/2026
- Anthony Petrone from Mizuho set a target price of $90.0 on 12/17/2025
- David Rescott from Baird set a target price of $99.0 on 12/15/2025
- Rohin Patel from JP Morgan set a target price of $74.0 on 12/12/2025
- Joanne Wuensch from Citigroup set a target price of $88.0 on 12/11/2025
- Mike Matson from Needham set a target price of $78.0 on 11/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
